Edgewise Therapeutics, Inc.
EWTX
Rangering i aksjer
#4051
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aksjekurs
$37.15
Sist synkronisert: 2026-10-16
Markedsverdi
$4.00B
Endring (1 dag)
-2.75%
Endring (1 år)
146.68%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
EPS for Edgewise Therapeutics, Inc. (EWTX)
EPS per June 2026 TTM: $-1.85
Ifølge de siste økonomiske rapportene og aksjekursen til Edgewise Therapeutics, Inc. er selskapets nåværende EPS (TTM) $-1.85. Ved slutten av 2023 hadde selskapet en EPS på $-1.57, en økning sammenlignet med EPS-en i 2022 som var $-1.26.
EPS-historikk for Edgewise Therapeutics, Inc. fra 2019 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
